Marika Guercio Selected Research

Therapeutics

4/2023	GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
1/2023	Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies.
1/2023	Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy.
1/2021	Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marika Guercio Research Topics

Disease

9	Neoplasms (Cancer) 03/2024 - 06/2014
3	COVID-19 01/2022 - 10/2021
2	Neuroblastoma 04/2023 - 01/2018
2	Cytokine Release Syndrome 01/2023 - 01/2021
2	Infections 11/2021 - 10/2021
2	Leukemia 01/2021 - 01/2021
2	Lymphoma (Lymphomas) 01/2021 - 01/2021
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2021 - 01/2021
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 01/2021
1	Macrophage Activation Syndrome 01/2023
1	Vitiligo 01/2023
1	Melanoma (Melanoma, Malignant) 01/2023
1	Hemorrhage 01/2023
1	Necrosis 11/2022
1	Bruton type agammaglobulinemia 11/2021
1	Primary Immunodeficiency Diseases 10/2021
1	Brain Diseases (Brain Disorder) 01/2021
1	Hodgkin Disease (Hodgkin's Disease) 01/2021
1	B-Cell Leukemia (Leukemia, B Cell) 01/2021
1	Sarcoma (Soft Tissue Sarcoma) 01/2020
1	Medulloblastoma 01/2018
1	Carcinoma (Carcinomatosis) 06/2014
1	Ovarian Neoplasms (Ovarian Cancer) 06/2014

Drug/Important Bio-Agent (IBA)

5	Chimeric Antigen ReceptorsIBA 04/2023 - 01/2018
3	CytokinesIBA 11/2022 - 01/2018
2	AP 1903 reagentIBA 03/2024 - 01/2021
2	Caspase 9IBA 04/2023 - 01/2021
2	AntibodiesIBA 01/2023 - 01/2022
2	BNT162 VaccineIBA 11/2021 - 10/2021
2	VaccinesIBA 11/2021 - 10/2021
2	Immunoglobulin G (IgG)IBA 11/2021 - 10/2021
2	Interleukin-15 (Interleukin 15)IBA 01/2021 - 01/2018
2	AntigensIBA 01/2021 - 01/2018
2	Interleukin-7 (Interleukin 7)IBA 01/2021 - 01/2018
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2023
1	Apoptosis Regulatory ProteinsIBA 01/2023
1	Interleukin-17 (Interleukin 17)IBA 01/2023
1	EmapalumabIBA 01/2023
1	Granzymes (Granzyme)IBA 11/2022
1	Interferon-gamma (Interferon, gamma)IBA 11/2022
1	EpitopesIBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2020
1	GangliosidesIBA 01/2018
1	HLA-A Antigens (HLA-A)IBA 01/2018
1	PlatinumIBA 06/2014
1	dactolisibIBA 06/2014
1	ABT-737IBA 06/2014

Therapy/Procedure

4	Therapeutics 04/2023 - 01/2021
2	Immunotherapy 04/2023 - 01/2023
1	Drug Therapy (Chemotherapy) 01/2021